This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Kenji Takenaka, MD; Naoyuki Kawahara, MD; Kazuharu Yamamoto, MD; Kiyoshi Kajiyama, MD; Takashi Maeda, MD; Hidetoshi Itasaka, MD; Ken Shirabe, MD; Takashi Nishizaki, MD; Katsuhiko Yanaga, MD; Keizo Sugimachi, MD

Arch Surg. 1996;131(1):71-76.

Abstract
Objective
To evaluate the recent results of liver resection in patients with hepatocellular carcinoma.

Design
Retrospective study.

Setting
A university hospital in Japan.

Patients
Two hundred eighty patients who underwent liver resection with complete extirpation of hepatocellular carcinoma from 1985 to 1993.

Main Outcome Measures
Morbidity and survival after operation and the pathologic features of hepatocellular carcinoma according to the TNM classification of the International Union Against Cancer.

Results
More than 40% of the patients with stages I and II disease underwent a partial resection of the liver, whereas 50% of those with stages III and IVA were operated on with more than a bisegmentectomy. Fifty percent of all patients had no postoperative complications. The morbidities included intra-abdominal abscess (7%), bile leakage (5%), and hepatic failure (4%, of whom half died; mortality rate, 2%). Histopathologically, 32% of the stage I tumors were well differentiated (grade 1), while, in stage III, 56% had portal invasion and 61% had daughter lesions in the liver. The cumulative survival rates of patients with stages I, II, and III disease and all patients at 5 years were 69%, 52%, 32%, and 50%, respectively, while the disease-free survival rates at 5 years were 38%, 34%, 17%, and 29%, respectively.

Conclusion
The recent results of liver resection for hepatocellular carcinoma are generally satisfactory; however, the recurrence rate is still high.

(Arch Surg. 1996;131:71-76)

Author Affiliations
From the Departments of Surgery II (Drs Takenaka, Kawahara, Yamamoto, Itasaka, Shirabe, Nishizaki, Yanaga, and Sugimachi) and Pathology II (Drs Kajiyama and Maeda), Faculty of Medicine, Kyushu University, Fukuoka, Japan.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma
Huynh et al.
Clin. Cancer Res. 2008;14:6146-6153.
ABSTRACT | FULL TEXT  

Adenovirus-delivered CIAPIN1 small interfering RNA inhibits HCC growth in vitro and in vivo
Li et al.
Carcinogenesis 2008;29:1587-1593.
ABSTRACT | FULL TEXT  

Use of Vascular Clamping in Hepatic Surgery: Lessons Learned From 1260 Liver Resections
Ercolani et al.
Arch Surg 2008;143:380-387.
ABSTRACT | FULL TEXT  

AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma
Huynh et al.
Molecular Cancer Therapeutics 2007;6:2468-2476.
ABSTRACT | FULL TEXT  

Role of Growth Factor Receptor Bound Protein 7 in Hepatocellular Carcinoma
Itoh et al.
Mol Cancer Res 2007;5:667-673.
ABSTRACT | FULL TEXT  

Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma
Huynh et al.
Molecular Cancer Therapeutics 2007;6:138-146.
ABSTRACT | FULL TEXT  

Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5
Liu et al.
Cancer Res. 2006;66:11851-11858.
ABSTRACT | FULL TEXT  

Overexpression of tumour suppressor retinoblastoma 2 protein (pRb2/p130) in hepatocellular carcinoma
Huynh
Carcinogenesis 2004;25:1485-1494.
ABSTRACT | FULL TEXT  

Elevated Expression of Valosin-Containing Protein (p97) in Hepatocellular Carcinoma Is Correlated With Increased Incidence of Tumor Recurrence
Yamamoto et al.
JCO 2003;21:447-452.
ABSTRACT | FULL TEXT  

A Possible Role for Insulin-like Growth Factor-binding Protein-3 Autocrine/Paracrine Loops in Controlling Hepatocellular Carcinoma Cell Proliferation
Huynh et al.
Cell Growth Differ. 2002;13:115-122.
ABSTRACT | FULL TEXT  

The Impact of New Technology on Hepatic Resection for Malignancy
Papadimitriou et al.
Arch Surg 2001;136:1307-1313.
ABSTRACT | FULL TEXT  

Clinicopathologic Features of Long-Term Survivors and Disease-Free Survivors After Resection of Hepatocellular Carcinoma: A Study of a Prospective Cohort
Poon et al.
JCO 2001;19:3037-3044.
ABSTRACT | FULL TEXT  

Hepatectomy for Hepatocellular Carcinoma: The Surgeon's Role in Long-term Survival
Fan et al.
Arch Surg 1999;134:1124-1130.
ABSTRACT | FULL TEXT  

Treatment Strategy for Patients With Cystic Lesions Mimicking a Liver Tumor: A Recent 10-Year Surgical Experience in Japan
Shimada et al.
Arch Surg 1998;133:643-646.
ABSTRACT | FULL TEXT  

A Thoracoabdominal Hepatectomy and a Transdiaphragmatic Hepatectomy for Patients With Cirrhosis and Hepatocellular Carcinoma
Takenaka et al.
Arch Surg 1998;133:80-83.
ABSTRACT | FULL TEXT  

Major Hepatic Resection: Indications and Results in a National Hospital System From 1988 to 1992
Nadig et al.
Arch Surg 1997;132:115-119.
ABSTRACT